Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Journal of Medical Economics|March 12, 2024
The economic burden of systemic lupus erythematosus in MexicoGihan Hamdy Elsisi, Lilia Andrade-Ortega, Margarita Portela, et al.
Frontiers in Neurology|November 29, 2023
The budget impact of alteplase in the treatment of acute ischemic stroke in EgyptHany Aref, Nevine El Nahas, Gihan Hamdy Elsisi, et al.
Journal of Medical Economics|February 6, 2024
Cost-effectiveness analysis of sodium zirconium cyclosilicate for hyperkalemia among patients with chronic kidney disease or heart failure in KuwaitGihan Hamdy Elsisi, Mohamed M Ibrahim Mahmoud, Khaldoon Al-Humood, et al.
Value in Health Regional Issues|November 21, 2021
Cost-Effectiveness of First-Line Cetuximab in Metastatic Colorectal Cancer in Saudi ArabiaShereef Elsamany, Gihan Hamdy Elsisi, Fayza Ahmed Mohamed Hassanin, et al.
Journal of Medical Economics|July 17, 2020
A budget impact analysis of lenalidomide in multiple myeloma Egyptian patientsGihan Hamdy Elsisi, João L Carapinha, Rania Afify, et al.
Journal of Medical Economics|January 31, 2023
Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in KuwaitAhmed Swidan, Gihan Hamdy Elsisi, Mohamed M Ibrahim, et al.
Value in Health Regional Issues|April 20, 2019
Safety-Engineered Syringes: An Intervention to Decrease Hepatitis C Burden in Developing Countries-A Cost-Effectiveness Analysis From EgyptAya Mostafa, Manal H El-Sayed, Mohamed El Kassas, et al.
Journal of Medical Economics|July 13, 2019
A budget impact analysis of budesonide/formoterol in patients with mild asthma in EgyptGihan Hamdy Elsisi, João Carapinha, Wagdy Amin, et al.
Global Journal on Quality and Safety in Healthcare|November 13, 2024
National Recommendations for Pharmacoeconomic Evaluations Reporting for Reimbursement and Procurement of New Pharmaceutical Applications in EgyptMary Gamal, Amal Samir Sedrak, Gihan Hamdy Elsisi, et al.
Journal of Medical Economics|December 12, 2024
The cost-effectiveness of treatment for high-risk, early-stage, triple-negative breast cancer in Egypt: an analysis of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumabBernadette Pöllinger, Amin Haiderali, Min Huang, et al.
Pageof 3